2017 Pediatric Rheumatology Symposium

May 17-20, 2017. Houston, Texas.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 77

Effectiveness of Childhood Vaccinations in CAPS Patients Treated With Canakinumab: Results From an Open-Label Phase III Extension Study
Abstract Number: 94

Effects of Age and Gender on Reference Levels of Biomarkers Comprising the Pediatric Renal Activity Index for Lupus Nephritis (p-RAIL)
Abstract Number: 5

Effects of Puberty on Systemic Lupus Erythematosus: Results of a multi-center prospective longitudinal observational study in children entering puberty with SLE
Abstract Number: 14

Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial
Abstract Number: 3

Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study
Abstract Number: 21

Enhancing Quality of Care in Childhood-Onset Systemic Lupus Erythematosus by Improving Performance on Quality Indicator Measures in Cardiovascular and Bone Health
Abstract Number: 20

Enthesitis-Related Arthritis: Non-Peripheral Pattern is Associated with an Expansion of Peripheral Th17 Populations
Abstract Number: 111

Eosinophilic Fasciitis in Children: Clinical Course and Response to Treatment from Two Large Academic Centers
Abstract Number: 147

Epigenetic and Transcriptomic Profiling of Primary Juvenile Idiopathic Arthritis Patient Cells: Better Understanding of Disease Pathogenesis
Abstract Number: 135

Epigenetic Profiling Of Juvenile Idiopathic Arthritis (JIA) Synovial Fluid Monocytes Points Towards a Role For Monocytes In Bone Damage
Abstract Number: 119

Establishment of registry for pediatric rheumatic diseases in Japan: Pediatric Rheumatology International Collaboration Unit Registry (PRICURE) survey
Abstract Number: 64

Evaluating Levels of Activity and Health-Related Quality of Life in a Pilot Cohort of Youth Athletes with Juvenile Idiopathic Arthritis
Abstract Number: 42

Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis
Abstract Number: 8

Examination of Reported Risk Loci from Candidate Gene Studies of Systemic Juvenile Idiopathic Arthritis Identifies Link between IL1RN Variation and both Disease Susceptibility and Response to Interleukin-1 Directed Therapy
Abstract Number: 113

Exploring the role of pediatric rheumatologists in the diagnosis and management of autoimmune encephalitis
Abstract Number: 141

Expression of Siglec-10 on Synovial Fluid CD14dim Monocytes Was Decreased in Juvenile Idiopathic Arthritis Patients

Jump to: View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].